[1] 郭天阳,杜安通,杨雅骊,等.第二代三唑类抗真菌药物的研究进展[J].世界临床药物,2014,35(12):715-718.
[2] CHUWONGWATTANA S,JANTARAROUNGTONG T,CHITASOMBAT M N,et al.A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis[J].Drug Metab Pharmacokinet,2016,31(2):117-122.
[3] XU G Q,ZHU L Q,GE T Y,et al.Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp.and Aspergillus spp.in children,adolescents and adults by Monte Carlo simulation[J].Int J Antimicrob Agents,2016,47(6):439-445.
[4] CABRAL-GALEANO E,RUIZ-CAMPS I,LEN-ABAD O,et al.Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital[J].Enferm Infecc Microbiol Clin,2015,33(5):298-302.
[5] LI Z W,PENG F H, YAN M,et al.Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients[J].Ther Drug Monit,2017,39(4):422-428.
[6] QI F,ZHU L,LI N,et al.Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole[J].Int J Antimicrob Agents,2017,49(4):403-409.
[7] WANG Y,WANG T,XIE J,et al. Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit[J].Pharmacotherapy,2016,36(7):757-765.
[8] BRESSÁN I G,MENDEZ M L,GIMENEZ M I.Validation of a reversed-phase ultra-high-performance liquid chromatographic method with photodiode array detection for the determination of voriconazole in human serum and its application to therapeutic drug monitoring[J].Ther Drug Monit,2018,40(2):276-283.
[9] LIN S C,LIN S W,CHEN J M,et al.Using sweeping-micellar electrokinetic chromatography to sweeping-micellar electrokinetic[J].Talanta,2010,82(2):653-659.
[10] PEREA S,PENNICK G J, MODAK A,et al.Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma[J].Antimicrob Agents Chemother,2000,44(5):1209-1213.
[11] 刘学松,何为群,陈文英,等.肺部真菌感染患者伏立康唑血药浓度监测的临床应用[J].国际呼吸杂志,2016,36(20):1521-1526.
[12] GROLL A H,TOWNSEND R,DESAI A,et al.Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P4503A4[J].Transpl Infect Dis,2017,19(5):e12751.